Drugs / ALS-002158
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01554085 | Dec 2011 → Sep 2012 | chronic hepatitis C virus infection | Alios Biopharma Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALS-002158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01554085 ↗ |
| Route | Oral | “Orally Administered ALS-002158” NCT01554085 ↗ |